title: Almotriptan: an effective and well-tolerated treatment for migraine pain.
abstract: The clinical data of almotriptan, the new selective 5-HT(1B/1D) agonist developed for the symptomatic treatment of migraine, are reviewed here. The pharmacokinetic performance of almotriptan is compared with that of other currently available triptans. The dose exhibiting the best efficacy/tolerability ratio of almotriptan is 12.5 mg. Efficacy of this almotriptan dose is comparable to that of the "gold" standard triptan, but with a lower recurrence rate. Gender or the presence of food in the stomach does not influence almotriptan's pharmacokinetic profile, and no relevant interactions of almotriptan with other medications have been reported. The tolerability of almotriptan is similar to that of placebo. Almotriptan's high efficacy together with its excellent tolerability and safety profile confirm this new 5-HT(1B/1D) agonist as a drug of choice for the symptomatic treatment of migraine attacks.
authors.affiliation: University Hospital Marques de Valdecilla, Santander, Spain.
authors.forename: Julio
authors.initials: J
authors.lastname: Pascual
mesh_terms: D002986:Clinical Trials as Topic; D006801:Humans; D007211:Indoles / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D008881:Migraine Disorders / Q000188:drug therapy* / Q000378:metabolism; D017366:Serotonin Receptor Agonists / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D014363:Tryptamines
chemical_list: D007211:Indoles; D017366:Serotonin Receptor Agonists; D014363:Tryptamines; C409045:almotriptan